Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs). Discover the innovative approaches to nasal sprays, and learn about the significant strides being made in transitioning to environmentally friendly, low-global warming potential (GWP) propellants in pressurized metered-dose inhalers (pMDIs). Nanopharm’s commitment to advancing pharmaceutical technologies and delivering client-focused solutions is at the forefront of Rob’s discussion.
![Nanopharm's Webinar Accelerate DPI Clinical Success with Innovative De-Risking Strategy](https://nanopharm.co.uk/wp-content/uploads/2024/07/Webinar-Accelerate-DPI-Clinical-Success-with-Innovative-De-Risking-Strategy-300x195.png)
Innovation & Insights
Accelerate DPI Clinical Success with Innovative De-Risking Strategy
Discover the comprehensive session of ‘Empowering the Path to Clinical: Innovative Strategies for De-Risking DPI Product Development’ from RDD 2024.